HHS awards $72.1M Other Transaction Agreement for COVID-19 response capacity expansion

Contract Overview

Contract Amount: $72,104,360 ($72.1M)

Contractor: Global Life Sciences Solutions USA LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2023-08-01

End Date: 2038-12-31

Contract Duration: 5,631 days

Daily Burn Rate: $12.8K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: COST SHARING

Sector: Healthcare

Official Description: OTHER TRANSACTION AGREEMENT: CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUPPORT OF PUBLIC HEALTH EMERGENCIES

Place of Performance

Location: MARLBOROUGH, MIDDLESEX County, MASSACHUSETTS, 01752

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $72.1 million to GLOBAL LIFE SCIENCES SOLUTIONS USA LLC for work described as: OTHER TRANSACTION AGREEMENT: CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUPPORT OF PUBLIC HEALTH EMERGENCIES Key points: 1. Contract focuses on pharmaceutical preparation manufacturing, crucial for public health emergencies. 2. Long duration (over 15 years) suggests a strategic, long-term investment in preparedness. 3. Awarded as a sole-source Other Transaction Agreement, bypassing traditional competitive bidding. 4. Cost-sharing arrangement indicates shared financial risk and commitment between government and contractor. 5. Potential for significant impact on pharmaceutical supply chain resilience. 6. Contract value is substantial, reflecting the scale of the public health need.

Value Assessment

Rating: fair

The contract value of $72.1 million over approximately 15 years is difficult to benchmark without specific details on the scope of 'capacity expansion' and the nature of the cost-sharing. Other Transaction Agreements (OTAs) are often used for research and development or prototyping, where traditional cost structures may not apply. However, for manufacturing capacity, a comparison to similar long-term supply agreements or capital investments in pharmaceutical manufacturing would be necessary to assess value for money. The cost-sharing mechanism implies a degree of financial prudence, but the overall pricing effectiveness is unclear without more context on the services and goods procured.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded as a sole-source Other Transaction Agreement (OTA). OTAs are a flexible contracting tool often used for research, development, and prototyping, allowing for streamlined processes and unique partnership structures. However, sole-source awards bypass the competitive bidding process, meaning there was no formal solicitation for multiple vendors to propose solutions. This approach is typically justified when a specific entity possesses unique capabilities or when speed is paramount. The lack of competition means that price discovery through market forces was not utilized.

Taxpayer Impact: Sole-source awards can limit opportunities for taxpayers to benefit from competitive pricing. While OTAs can foster innovation, the absence of competition means the government may not achieve the lowest possible cost for the services or goods acquired.

Public Impact

The primary beneficiaries are the American public, through enhanced preparedness for COVID-19 and future public health emergencies. The contract supports the expansion of pharmaceutical manufacturing capacity, ensuring a more robust supply chain for critical medical countermeasures. Geographic impact is likely national, aiming to bolster domestic manufacturing capabilities. Workforce implications could include job creation in the pharmaceutical manufacturing sector, particularly in specialized roles related to production and quality control.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition raises concerns about potential overpricing and reduced value for taxpayer dollars.
The long contract duration could lead to inflexibility if public health needs or technological advancements shift.
Reliance on a single source for critical capacity expansion may create supply chain vulnerabilities if the contractor faces operational issues.
The 'cost-sharing' nature requires careful monitoring to ensure the government's share is justified and the contractor's contribution is substantial.

Positive Signals

Addresses a critical need for public health emergency preparedness, aligning with national security objectives.
The Other Transaction Agreement mechanism allows for flexibility and speed, potentially accelerating the build-up of essential manufacturing capacity.
Cost-sharing demonstrates a commitment from the contractor, potentially leading to more efficient resource utilization.
The long-term nature of the contract suggests a strategic investment in resilience, rather than a short-term fix.

Sector Analysis

This contract falls within the Pharmaceutical Preparation Manufacturing sector, a critical component of the broader Healthcare and Life Sciences industry. The market for pharmaceutical manufacturing capacity is substantial, driven by global demand for medicines and increasing focus on supply chain security. This contract represents a significant government investment aimed at bolstering domestic capabilities, potentially influencing market dynamics by increasing available capacity and encouraging technological advancements in production processes. Comparable spending benchmarks would typically involve analyzing investments in similar manufacturing infrastructure or long-term supply agreements for critical medical supplies.

Small Business Impact

The contract data indicates that this is not a small business set-aside (ss: false, sb: false). Therefore, there are no direct subcontracting implications for small businesses mandated by this specific award. The focus is on expanding overall capacity, and while the prime contractor may engage small businesses in its supply chain, there is no explicit requirement within this contract to do so. The impact on the small business ecosystem is indirect and depends on the prime contractor's procurement practices.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS), specifically the Office of the Assistant Secretary for Preparedness and Response (ASPR). As an Other Transaction Agreement, the oversight mechanisms might differ from traditional FAR-based contracts, often relying on the terms negotiated within the OTA itself. Accountability measures would be defined by the agreement's milestones, reporting requirements, and cost-sharing provisions. Transparency may be limited due to the sole-source nature and the flexibility inherent in OTAs, though ASPR is generally subject to public scrutiny and reporting requirements. Inspector General jurisdiction would likely apply to ensure the proper use of federal funds.

Related Government Programs

COVID-19 Response Efforts
Public Health Emergency Preparedness
Medical Countermeasure Manufacturing
Pharmaceutical Supply Chain Security
Strategic National Stockpile Augmentation

Risk Flags

Sole-source award bypasses competition
Long contract duration may reduce flexibility
Potential for cost overruns due to lack of competitive pricing
Dependence on a single contractor for critical capacity

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $72.1 million to GLOBAL LIFE SCIENCES SOLUTIONS USA LLC. OTHER TRANSACTION AGREEMENT: CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUPPORT OF PUBLIC HEALTH EMERGENCIES

Who is the contractor on this award?

The obligated recipient is GLOBAL LIFE SCIENCES SOLUTIONS USA LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $72.1 million.

What is the period of performance?

Start: 2023-08-01. End: 2038-12-31.

What specific pharmaceutical preparations or capabilities is this contract intended to expand?

The provided data indicates the contract is for 'CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUPPORT OF PUBLIC HEALTH EMERGENCIES' within 'Pharmaceutical Preparation Manufacturing'. However, the specific types of preparations or the exact nature of the capacity expansion (e.g., vaccine production, antiviral manufacturing, diagnostic reagent production) are not detailed in the summary data. This level of specificity is crucial for understanding the contract's precise contribution to public health preparedness and for evaluating its value. Further analysis would require reviewing the full contract documentation to identify the targeted products or manufacturing processes.

How does the 'cost-sharing' arrangement work, and what is the government's expected contribution versus the contractor's?

The 'cost-sharing' (pt: COST SHARING) aspect of this Other Transaction Agreement (OTA) implies that both the government and GLOBAL LIFE SCIENCES SOLUTIONS USA LLC will bear a portion of the costs associated with expanding the pharmaceutical manufacturing capacity. The exact percentages or fixed amounts for each party's contribution are not specified in the provided data. Typically, cost-sharing in OTAs is negotiated based on the project's nature, the perceived risk, and the potential benefits to each party. This arrangement aims to align incentives and ensure the contractor has a vested interest in the project's success and cost-efficiency. A detailed review of the OTA's terms and conditions would be necessary to ascertain the precise cost-sharing formula and the government's financial exposure.

What are the key performance indicators (KPIs) and milestones for this contract, and how will performance be measured?

The provided data does not include specific Key Performance Indicators (KPIs) or milestones for this contract. For an Other Transaction Agreement focused on capacity expansion, KPIs would likely relate to the successful establishment or enhancement of manufacturing lines, production output targets, quality control metrics, and adherence to timelines for achieving operational readiness. Performance measurement would involve regular reporting from the contractor, site visits, and potentially independent verification of achieved capacity and readiness. The long duration (ending 2038) suggests that performance will be assessed over multiple phases or stages of capacity development and maintenance.

What is the track record of GLOBAL LIFE SCIENCES SOLUTIONS USA LLC in fulfilling large-scale government contracts, particularly in pharmaceutical manufacturing or emergency preparedness?

Information regarding the specific track record of GLOBAL LIFE SCIENCES SOLUTIONS USA LLC in fulfilling large-scale government contracts, especially within pharmaceutical manufacturing or emergency preparedness, is not provided in the summary data. A comprehensive assessment would require examining the company's past performance on similar contracts, including their success in meeting deadlines, quality standards, and budget requirements. Given this is an OTA, the government likely assessed the contractor's capabilities and past performance prior to the sole-source award. However, without access to that assessment or public performance records, it's difficult to definitively evaluate their suitability based solely on the provided contract details.

How does the $72.1 million investment compare to historical government spending on pharmaceutical manufacturing capacity expansion for public health emergencies?

The $72.1 million awarded for this capacity expansion is a significant investment. To benchmark it against historical spending, one would need to analyze previous government initiatives aimed at bolstering pharmaceutical manufacturing for emergency preparedness, such as those related to H1N1, Ebola, or previous pandemic responses. This would involve looking at the total funding allocated to similar programs, the types of agreements used (e.g., traditional contracts, OTAs), and the scale of capacity built. Without such comparative data, it's challenging to determine if this investment is high, low, or in line with previous efforts. The long duration (over 15 years) also suggests a different strategic approach compared to potentially shorter-term surge capacity contracts.

What are the potential risks associated with a sole-source Other Transaction Agreement for critical manufacturing capacity?

Sole-source OTAs for critical manufacturing capacity carry several potential risks. Firstly, the lack of competition can lead to higher costs for taxpayers, as there is no market pressure to drive down prices. Secondly, the government may not benefit from the innovative solutions that a competitive bidding process could yield. Thirdly, reliance on a single contractor can create supply chain vulnerabilities; if the contractor experiences operational issues, delays, or fails to perform, the intended capacity expansion could be jeopardized. Finally, the flexibility of OTAs, while beneficial, can sometimes lead to less stringent oversight compared to traditional contracts, potentially increasing the risk of mismanagement or inefficient use of funds if not carefully monitored.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: QUALITY CONTROL, TEST, INSPECTION › OTHER QUALITY, TEST, INSPECT SVCS

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: COST SHARING (T)

Evaluated Preference: NONE

Contractor Details

Parent Company: Danaher Corporation

Address: 100 RESULTS WAY, MARLBOROUGH, MA, 01752

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $72,104,360

Exercised Options: $72,104,360

Current Obligation: $72,104,360

Actual Outlays: $61,137,358

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline